Maria C. Lucana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria C. Lucana has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Benjamí Oller-Salvia
Department of Bioengineering, Institut Químic de Sarrià (IQS) – Universitat Ramon Llull, Barcelona, Spain
2 shared publications - Albert Roig
Grup d’Enginyeria de Materials (GEMAT), Institut Químic de Sarrià (IQS), Universitat Ramon Llull, 08017 Barcelona, Spain
1 shared publication - Emilia Petrachi
Grup d’Enginyeria de Materials (GEMAT), Institut Químic de Sarrià (IQS), Universitat Ramon Llull, 08017 Barcelona, Spain
1 shared publication - Roberta Lucchi
Grup d’Enginyeria de Materials (GEMAT), Institut Químic de Sarrià (IQS), Universitat Ramon Llull, 08017 Barcelona, Spain
1 shared publication - Salvador Borrós
Grup d'Enginyeria de Materials (GEMAT), Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Spain
1 shared publication - Shambhavi Pandey
Institut Quimic de Sarria, Ramon Llull University, Barcelona, 08017, Spain
1 shared publication
Latest Publications
- Open Access
- 25 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Development of simplified, photo-active, and TfR1-targeted poly(β-aminoester)-zwitterion nanovehicles for gene delivery across brain endothelium
Although nucleotide-based therapeutics hold promise for a variety of diseases, their clinical application is limited because of low stability and poor bioavailability. Among non-viral gene delivery vectors, poly(β-aminoester)s (pBAEs) stand out because of their low cytotoxicity, high transfection capacity, and adequate biodegradation profile. Oligopeptide end-Modified pBAEs (OM-pBAEs) enable enhanced polynucleotide encapsulation, cellular internalization, and transfection. Despite the outstanding properties of OM-pBAEs as non-viral gene delivery vectors, traditional OM-pBAE formulations have low cell selectivity and require formulation with two or more polymers. In this study, we first develop a simplified OM-pBAE formulation with a single polymer (pBAE-CRHR) and then add a zwitterionic moiety as part of the end-capping process (pBAE-CRHR-Zw). Subsequently, we show that addition of a photo-cleavable moiety enabled selective recovery of transfection capacity. Finally, we functionalize pBAE-CRHR-Zw with BrainBike-4, a bicyclic peptidomimetic binding transferrin receptor 1, and show that the targeted polyplexes display improved capacity to transfect cells with high levels of TfR1 and to transmigrate in a human cell-based model of the BBB.
- 25 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of simplified, photo-active, and TfR1-targeted poly(β-aminoester)-zwitterion nanovehicles for gene delivery across brain endothelium
Although nucleotide-based therapeutics hold promise for a variety of diseases, their clinical application is limited because of low stability and poor bioavailability. Among non-viral gene delivery vectors, poly(β-aminoester)s (pBAEs) stand out because of their low cytotoxicity, high transfection capacity, and adequate biodegradation profile. Oligopeptide end-Modified pBAEs (OM-pBAEs) enable enhanced polynucleotide encapsulation, cellular internalization, and transfection. Despite the outstanding properties of OM-pBAEs as non-viral gene delivery vectors, traditional OM-pBAE formulations have low cell selectivity and require formulation with two or more polymers. In this study, we first develop a simplified OM-pBAE formulation with a single polymer (pBAE-CRHR) and then add a zwitterionic moiety as part of the end-capping process (pBAE-CRHR-Zw). Subsequently, we show that addition of a photo-cleavable moiety enabled selective recovery of transfection capacity. Finally, we functionalize pBAE-CRHR-Zw with BrainBike-4, a bicyclic peptidomimetic binding transferrin receptor 1, and show that the targeted polyplexes display improved capacity to transfect cells with high levels of TfR1 and to transmigrate in a human cell-based model of the BBB.
- Open Access
- 2 December 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (12) , 2065
Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics
Peptides show high promise in the targeting and intracellular delivery of next-generation bio- and nano-therapeutics. However, the proteolytic susceptibility of peptides is one of the major limitations of their activity in biological environments. Numerous strategies have been devised to chemically enhance the resistance of peptides to proteolysis, ranging from N- and C-termini protection to cyclization, and including backbone modification, incorporation of amino acids with non-canonical side chains and conjugation. Since conjugation of nanocarriers or other cargoes to peptides for targeting and cell penetration may already provide some degree of shielding, the question arises about the relevance of using protease-resistant sequences for these applications. Aiming to answer this question, here we provide a critical review on protease-resistant targeting peptides and cell-penetrating peptides (CPPs). Two main approaches have been used on these classes of peptides: enantio/retro-enantio isomerization and cyclization. On one hand, enantio/retro-enantio isomerization has been shown to provide a clear enhancement in peptide efficiency with respect to parent L-amino acid peptides, especially when applied to peptides for drug delivery to the brain. On the other hand, cyclization also clearly increases peptide transport capacity, although contribution from enhanced protease resistance or affinity is often not dissected. Overall, we conclude that although conjugation often offers some degree of protection to proteolysis in targeting peptides and CPPs, modification of peptide sequences to further enhance protease resistance can greatly increase homing and transport efficiency.
- 2 December 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (12) , 2065
Open AccessProtease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics
Peptides show high promise in the targeting and intracellular delivery of next-generation bio- and nano-therapeutics. However, the proteolytic susceptibility of peptides is one of the major limitations of their activity in biological environments. Numerous strategies have been devised to chemically enhance the resistance of peptides to proteolysis, ranging from N- and C-termini protection to cyclization, and including backbone modification, incorporation of amino acids with non-canonical side chains and conjugation. Since conjugation of nanocarriers or other cargoes to peptides for targeting and cell penetration may already provide some degree of shielding, the question arises about the relevance of using protease-resistant sequences for these applications. Aiming to answer this question, here we provide a critical review on protease-resistant targeting peptides and cell-penetrating peptides (CPPs). Two main approaches have been used on these classes of peptides: enantio/retro-enantio isomerization and cyclization. On one hand, enantio/retro-enantio isomerization has been shown to provide a clear enhancement in peptide efficiency with respect to parent L-amino acid peptides, especially when applied to peptides for drug delivery to the brain. On the other hand, cyclization also clearly increases peptide transport capacity, although contribution from enhanced protease resistance or affinity is often not dissected. Overall, we conclude that although conjugation often offers some degree of protection to proteolysis in targeting peptides and CPPs, modification of peptide sequences to further enhance protease resistance can greatly increase homing and transport efficiency.